Group 1 - In October, five funds under GF Fund experienced declines exceeding 10%, including the Hong Kong Innovative Medicine ETF and two classes of the GF CSI Hong Kong Innovative Medicine ETF (QDII) [1][2] - The GF CSI Hong Kong Innovative Medicine ETF (QDII) fell by 11.61% in October, with its top ten holdings including companies like Innovent Biologics and BeiGene [1][2] - The GF Hong Kong Stock Connect Growth Selected Stocks C and A classes dropped by 10.42% and 10.40% respectively, with cumulative returns of -29.52% and -30.99% since their inception in September 2020 [1][2] Group 2 - The top ten holdings of the GF Hong Kong Stock Connect Growth Selected Stocks include Alibaba, Tencent, and Xiaomi, reflecting a focus on major technology and biotech firms [2][3] - Liu Jie has managed the first three funds mentioned, while Li Yaozhu has been managing the GF Hong Kong Stock Connect Growth Selected Stocks since its establishment [1][3] - The cumulative net values for the A and C classes of the GF Hong Kong Stock Connect Growth Selected Stocks are 0.7048 yuan and 0.6901 yuan respectively [1][3]

5月19日，广发港股通成长精选股票A（009896）下跌0.12%，最新净值0.61元，连续3个交易日下跌， 区间累计跌幅2%。 据了解，广发港股通成长精选股票A成立于2020年9月，基金规模17.62亿元，成立来累计收益 率-39.35%。从持有人结构来看，截至2024年末，广发港股通成长精选股票A的基金机构持有4.05亿份， 占总份额的13.38%，个人投资者持有26.25亿份，占总份额的86.62%。 公开信息显示，现任基金经理李耀柱先生:理学硕士,持有中国证券投资基金业从业证书。现任广发基金 管理有限公司国际业务部总经理、广发沪港深新起点股票型证券投资基金基金经理(自2016年11月9日起 任职)、广发港股通成长精选股票型证券投资基金基金经理(自2020年9月10日起任职)、广发全球科技三 个月定期开放混合型证券投资基金(QDII)基金经理(自2021年3月3日起任职)、广发全球精选股票型证券 投资基金基金经理(自2021年4月7日起任职)、广发沪港深价值成长混合型证券投资基金基金经理(自2021 年6月22日起任职)、广发沪港深行业龙头混合型证券投资基金基金经理(自2025年2月10日起任职)。曾任 ...